Supplementary Data from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced &lt;i&gt;BRAFV600&lt;/i&gt;-mutant Melanoma